PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsChinese scientists to begin first human CRISPR trial

BioNews

Chinese scientists to begin first human CRISPR trial

Published 9 January 2017 posted in News and appears in BioNews 861

Author

Rachel Siden

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Chinese scientists plan to start the first-ever clinical trial of CRISPR genome-editing technology in humans — on patients with lung cancer — this August...

Chinese scientists plan to start the first-ever clinical trial of CRISPR genome-editing technology in humans – on patients with lung cancer – this August.

The trial will primarily test the safety of the technique. It is similar to a planned US clinical trial using CRISPR to treat three types of cancer, which has received approval from the US Food and Drug Administration, but is still awaiting full approval to go ahead.

The planned treatment involves injected genetically edited immune T cells into patients with metastatic non-small-cell lung cancer who have failed to respond to conventional chemotherapy. 'Treatment options are very limited,' Dr Lu You, lead researcher and oncologist at Sichuan University West China Hospital, told Nature News. 'This technique is of great promise in bringing benefits to patients, especially the cancer patients whom we treat every day.'

The Chinese team will use CRISPR/Cas9 to delete a gene that encodes the PD-1 protein in T cells extracted from the patient's blood. The PD-1 protein normally keeps the immune system in check to prevent T cells from attacking healthy cells. These modified T cells will then be multiplied and injected back into the patient to activate an immune response against the cancer.

The trial will involve ten patients. For safety, the first three participants will be tested one at a time, and each one will be observed for two months before moving to the next patient.

The main safety concern is that, by deleting the PD-1 gene, the activated T-cells could attack healthy cells. However, trials involving PD-1 antibodies, which work in a similar way, have not shown these effects. Last November, a baby in London was also successfully treated for advanced leukaemia using T cells that had been modified using the genome-editing technique TALENs (see BioNews 827).

A second safety concern is that CRISPR could create 'off-target' effects – inadvertently deleting the wrong gene. But a biotechnology company collaborating on the trial, Chengdu MedGenCell, will examine all T cells to ensure the correct gene is deleted before the T cells are injected back into the patient.

Ethical approval for the trial took just six months, which is fast by western standards. There have been criticisms of China for not being cautious enough in this area. Chinese scientists were the first to genetically edit human embryos (see BioNews 799).  'When it comes to gene editing, China goes first,' Tetsuya Ishii, a bioethicist at Hokkaido University in Sapporo, Japan, told Nature News.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 February 2018 • 2 minutes read

China has treated 86 people with CRISPR genome editing

by Meghna Kataria

China has administered CRISPR/Cas9 genome editing to at least 86 cancer patients, a new report has revealed. 

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 May 2017 • 2 minutes read

Genome editing successfully treats leukaemia

by Dr Loredana Guglielmi

Doctors at London's Great Ormond Street Hospital have used genome editing to successfully treat two children with leukaemia...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
25 November 2016 • 2 minutes read

China begins first CRISPR human therapy trial

by Anneesa Amjad

Chinese scientists have injected CRISPR/Cas9 gene-edited cells into a human for the first time...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
19 September 2016 • 2 minutes read

TV Review: Panorama — Medicine's Big Breakthrough: Editing Your Genes

by Rhys Baker

Over just 30 minutes Fergus Walsh has a lot of ground to cover here without even touching on the ethical debate. Yet, while gene editing may have 'just been made simple', how we respond to these stunning advances is anything but...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 September 2016 • 2 minutes read

US regulator weighs up CRISPR cancer therapy trial

by Rachel Reeves

A US federal safety board is set to review an application for the first in-human use of CRISPR/Cas9 genome-editing technology to treat cancer...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 September 2016 • 3 minutes read

CRISPR cancer therapy trial gets go-ahead in US

by Rachel Reeves

The first in-human use of the genome-editing technology CRISPR has been approved by a US federal safety board...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
14 September 2016 • 2 minutes read

CRISPR shrinks tumours in mice

by Dr Özge Özkaya

Scientists from China have managed to shrink the size of tumours in mice using CRISPR/Cas9 genome-editing technology...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
30 August 2016 • 5 minutes read

Book Review: GMO Sapiens - The Life-Changing Science of Designer Babies

by Julian Hitchcock

GMO Sapiens is just the annoying grit in the machine that the genome editing debate needs, but readers deserve clearer lines between science, speculation and opinion...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
12 April 2016 • 3 minutes read

Second Chinese team create genetically modified human embryos

by Ayala Ochert

A second team in China report that they have created genetically modified human embryos, in an attempt to make them resistant to HIV, using the genome-editing technique CRISPR/Cas9...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 February 2016 • 2 minutes read

Editas goes public despite CRISPR patent battle

by Cait McDonagh

A biotechnology company co-founded by two leading scientists involved in developing the genome-editing technology, CRISPR/Cas9, has gone public, raising over $94 million in its initial share offering...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Nuffield Council publishes preliminary ethical review of genome editing

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856